Determination of Dimenhydrinate Nasal Delivery System in the Blood by RP-LC

Dimenhydrinate (DM) is used therapeutically for the prevention of motion sickness associated with nausea and vomiting. The aim of this investigation is the development of a new, rapid, sensitive, simple and fully validated RP-LC procedure for the suitable assay of DM in pharmaceutical formulation applied in blood samples. The method was validated before the amount determination studies in order to confirm linearity, precision, accuracy, selectivity, determination and quantification limit and consistency. High determination coefficient (r ²  = 0.998) of the standard curve drawn in the linearity studies showed that the line equation can be used in the quantification of the DM. Literature was reviewed for the methods based on diphenhydramine (DIP), its metabolite dimenhydrinate, in the in vivo determination of dimenhydrinate amount. The most appropriate method to be used in LC was decided to be the method applied by benefitting from the fluorescence characteristic of DIP. Maximum excitation and emission wavelengths in the developed method were scanned using multiple wavelengths and, maximum excitation and emission wavelengths were found to be 215 and 300 nm, respectively. In the validation study used to prove validity of the method, determination coefficient of the developed standard curve was calculated as 0.998 (RSD %), and line equation was concluded to be appropriate for use in amount determination studies. BBS % (1.06, 1.84 %) values obtained as “<2 %” in the intra-day and inter-day precision studies proved the precision of the method. Selectivity study revealed that other materials used in the formulation did not exhibit absorbance in the same wavelengths. Detection and quantification limit were found as 1 and 5 ng mL^?1, respectively. The determination of DM plasma concentrations using the proposed and fully validated LC assay has allowed us to characterize DMPK in the sheep, as well as determine DM relative bioavailability.